header-12
Translational Research

Presentations 2016

Scientific meetings where APCRC-Q researchers have been invited to speak in 2016 include:

The Prostate Cancer Workshop at the Brisbane Cancer Conference, Brisbane, 24-25 November 2016

Oral: Gunter J, Insulin in prostate cancer progression
Oral: Philp L, Adipokines and metabolic regulation of prostate cancer
Oral: Sadowski M, Lipids fueling prostate cancer treatment resistance
Oral: Volpert M, Targeting NRP1 in advanced prostate cancer
Oral: Kryza T, Proteases in the tumour microenviroment activated by treatment
Oral: Bock N, Bioengineered 3D models for cancer
Oral: Hollier B, Tumour plasticity and role of EMT
Oral: Tevz G, Transcriptional read through; it is not always as it seems
Oral: Taherian Fard A, Computational approach to understanding gene networks

Oral: Shokoohmand A, Bock N, Baldwin J, Kryza T, Nelson CC, Clements JA, Hutmacher DW. Development and validation of a modular 3D microenvironment platform technology for studying prostate cancer-induced bone metastasis

IHBI Postgraduate Student Conference, Gold Coast, 10-11 November 2016:

Oral: Matin F, Moya L, Jeet V, Clements J, Batra J. The Clinical Utility of Plasma MicroRNA Biomarkers for the Detection of Aggressive Prostate Cancer. (Runner Up Best Oral).

Oral: Rhee H. Androgen Deprivation Therapy and Adjuvant Metformin (ADMET) Trial: Randomized, Single Blinded, Placebo Controlled Trial.

Oral: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Ratther E, Sweeney K, Stylianou N, Tevz G, Volpert M, Hu Q, Nelson CC, Williams ED, Hollier BG. Investigating the role of epithelial plasticity in the development of therapy-induced neuroendocrine prostate cancer.

Poster: Hu R, Sweeney K, Williams ED, Russell PJ, Nelson CC, Hollier BG. Monitoring prostate cancer xenograft growth and oxygen distribution using the VEVO LAZR imaging system.

Poster: Joshi A, Nicholson C, Hutchinson A, McPherson S, Gunter J, Williams E, Nelson C, Rhee H, Vela I, In vitro culture of metastatic prostate cancer using novel organoid in vitro culture technology.

Poster: Srinivasan S, Stephens C, Spurdle A, Koistinen H, The Practical Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Two SNPs in PSA modulate prostate cancer risk and have functional consequences that may potentially improve assessment of the current PSA test.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson C, Clements J, Batra J. Deciphering the functional roles of the MCAT and PDK1 genes in prostate cancer.

Poster: Stylianou N, Lehman LL, Wang C, Jovanovic L, Rocktroh A, Taherian Fard A, Sadowski M, Ward M, Kashyap A, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG. Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in mCRPC.

The Australian Bioinformatics and Computational Biology Society/Big Biology and Bioinformatics Symposium combined meeting, Brisbane, 1-2 November 2016.

Oral: Fuhrman-Luck RA, Hastie ML, Stoll T, Kleifeld O, Ho BK, Lehman ML, Rockstroh A,  Kryza T, Stephens CR, Nelson CC, Gorman JJ, Loessner D, Clements JA. Big data from a little proteolysis: combining multiple omics approaches to identify novel functions of a protease associated with prostate cancer.(Runner up prize best oral presentation by an early career researcher)

The Translational Research Institute (TRI) Symposium 2016, Brisbane, 25 October 2016

Oral: Kryza T, Tevz G, Mc Pherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Kallikrein-related peptidase 14 is upregulated after androgen targeting therapies and involved in aggressive prostate cancer.

Oral: Fuhrman-Luck RA, Hastie ML, Stoll T, Kleifeld O, Ho BK, Lehman ML, Rockstroh A,  Kryza T, Stephens CR, Nelson CC, Gorman JJ, Loessner D, Clements JA, An emerging driver of prostate cancer progression. (Award: Best oral presentation by a post-doctoral researcher).

Poster: Kryza T, Fuhrman-Luck R, Stephens C, Lawrence M, Risbridger G, Clements J, Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate derived fibroblasts. (Poster prize, ECR category).

Poster: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson C, Clements J, Batra J. Deciphering the functional roles of the MCAT and PDK1 genes in prostate cancer.

Poster: Srinivasan S, Stephens C, Spurdle A, Koistinen H, The Practical Consortium, The Australian Prostate Cancer BioResource, Clements J, Batra J. Functional validation of prostate cancer risk associated PSA germline variants.

Poster: Matin F, Moya L, Jeet V, Clements J, Batra J. The Clinical Utility of Plasma MicroRNA Biomarkers for the Detection of Aggressive Prostate Cancer. (Judges’ Choice Runner Up Science to Business Category).

ComBio 2016, Brisbane, 3-7 October 2016

Colloquium Presentation: Panchadsaram J, Tevz G, Stylianou N, Hollier B, Nelson C, The Australian Prostate Cancer Bioresource, Williams ED, Clements J, Batra J. Identification of a novel long non-coding RNA at the 5p15 locus associated with prostate cancer risk.

Oral: Matin F, Moya L, Jeet V, Clements J, Batra J. The Clinical Utility of Plasma MicroRNA Biomarkers for the Detection of Aggressive Prostate Cancer. 

Oral: Srinivasan S, Stephens C, Spurdle A, Koistinen H, The Practical Consortium, Australian Prostate Cancer BioResource, Clements J and Batra J. Functional annotation of prostate cancer risk associated PSA germline variants.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson C, Clements J, Batra J. Deciphering the functional roles of the MCAT and PDK1 genes in prostate cancer, Brisbane Cell and Developmental Biology Meeting 2016, 30 September 2016.

Podium: Vela I, Incorporating metastatic and liquid biopsies in clinical trials, 3rd Thomas Ashworth CTC Symposium, Sydney, 21 September 2016.

16th Biennial Conference of the Metastasis Research Society, Chengdu, China, 15-20 September 2016:

Invited Speaker: Williams ED, Combination of patient derived xenografts and a modular 3D microenvironment platform technology enable modelling of osteoblastic prostate cancer bone metastases.

Invited Speaker: Sweeney K, Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer.

The 17th Asia-Pacific Prostate Cancer Conference, Melbourne, 31 August – 3 September 2016:

Invited speaker: Sadowski M, Androgen-targeted therapies induce adaptive changes to the lipid fuel supply of advanced prostate cancer. 

Invited speaker: Volpert M, Revealing the plastic nature of metastatic castration resistant prostate cancer. 

Invited speaker: Clements J, Multifunctional roles of the kallikrein-related peptidases in the prostate cancer microenvironment.

Invited speaker: Batra J, miRNA related genetic variations are associated with risk of prostate cancer

Oral and Poster: Sweeney K, Stylianou N, Tevz G, Pirlo K, Upadhyaya A, Ratther E,  Lehman M, Gleave M, Gunter J, Williams ED, Nelson CC, Hollier B, Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer.

Oral and Poster: Shokoohmand A, Bock N, Baldwin J, Kryza T, Nelson CC, Clements JA, Hutmacher DW. Development and validation of a modular 3D microenvironment platform technology for studying prostate cancer-induced bone metastasis.

Oral and Poster: Panchadsaram J, Tevz G, Nelson C, Clements J, The PRACTICAL Consortium, Batra J. Prostate cancer risk associated INDEL at 5p15 regulates a novel long noncoding RNA (lncRNA) by affecting Androgen Receptor Binding.

Poster: Wagholikar A, A novel concept for design and evaluation of mobile technology based intervention for advanced prostate cancer patients.

Poster: Pandey S, Walpole C, Cabot PJ, Shaw PN, Batra J, Hewavitharana AK. Medium polarity fraction of papaya leaf juice has selective anti-proliferative effects on prostate cancer cells.

Poster: Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans C, Lehman M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Karnes J, Den R, Fazli L, Gleave M, Williams E, Rennie P, Buttyan R, Gunter J, Russell P, Nelson C, Hollier B. Targeting Neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.

Poster: Kryza T, Bock N, Shokoohmand A, Tevz G, Mc Pherson S, Lehman M, Stephens C,  Hollier B, Nelson C, Hutmacher D, Clements J. Modulation of protease expression in prostate cancer cells after androgen deprivation.

Poster: Panchadsaram J, Tevz G, Nelson CC, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Srinivasan S, Stephens C, Clements J, Batra J. Exploring the function of prostate cancer-associated germline variants in the PSA gene.

Poster: Subramaniam S, Walpole C, Clements J, Batra J. Determining the functional roles of MCAT and PDK1 genes in prostate cancer.

Poster: Thomas PB, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK. Targeting the Long Non-Coding RNA GHSROS, a Mediator of Prostate Cancer Tumour Growth, with Antisense Oligonucleotides.

Poster: Fuhrman-Luck R, Hastie M, Ho B, Stoll T, Stephens C, Kryza T, Rockstroh A, Lehman M,  Nelson C, Loessner D, Kleifeld O, Gorman J, Clements J. Use multi-omics platforms for comprehensive assessment of the mechanism of action of kallikrein-related peptidase 4 (KLK4) in the prostate tumour microenvironment.

Poster: Stylianou N, Lehman ML, Wang C, Jovanovic L, Rockstroh A, Ward M, Kashyap A, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG. Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in mCRPC.

Poster: Jeet V, Yeh M-C, Campbell DH, Walsh BJ, Russell PJ, Nelson CC. More than a Biomarker: Exploring the Role of Glypican-1 as a New Therapeutic Target for Prostate Cancer.

Poster: Matin F, Moya L, Jeet V, Clements J, Batra J. MicroRNAs in plasma: potential minimally invasive biomarkers for the detection of aggressive prostate cancer.

Poster: Protsenko A, Maharaj M, Lisle J, Herington A, Stephenson S-A. Optimising conditions for studying the interaction between EphB4 positive prostate cancer cells and ephrin-B2 positive endothelial cells.

Poster: Maharaj M, Mertens-Walker I,  Croll T, Lisle J, Stephens C, Walsh T, Herington A, Stephenson S-A. Development of a first-in-class antagonist to block EphB4 protein function via SUMOylation inhibition in prostate cancer.

Poster: Yeh M-C, Jeet V, Wissmueller S, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Glypican-1: a new biomarker for the detection of prostate cancer.

Poster: Chandra S, Tevz G, Moya L, Clements J, Batra J. The role of HNF1B (Hepatocyte Nuclear factor-1) in prostate cancer progression.

Poster: Ratther E, Sweeney K, Stylianou N, Tevz G, Volpert M, Hu Q, Nelson CC, Williams ED, Hollier BG. Investigating the role of epithelial plasticity in the development of therapy-induced neuroendocrine prostate cancer.

Poster: Philp LK, Tevz G, Sadowski MC, Lehman M, Gunter JH, Nelson CC. Implicating Glucagon-like peptide-1 in the hormone-dependent metabolic reprogramming observed in advanced prostate cancer.

Poster: Gunter J, Sadowski M, Philp L, Lee W, Sarkar P, Lehman M, McPherson S, Bartonicek N, Gupta R, Blanksby S, Hollier B, Nelson C. Profiling adaptive lipid metabolism in prostate cancer cells in response to androgen deprivation and hyperinsulinaemia.

Poster: Sadowski MC, McPherson SJ, Rockstroh A, Soekmadji C, Tevz G, Gunter JH, Jeet V, Nelson CC. Comprehensive profiling of androgen signalling and energy and lipid metabolism highlights heterogeneity of prostate cancer cell lines.

Invited speaker: Prof Colleen Nelson, Developing new therapies for advanced prostate cancer, Queenstown Molecular Biology - Cancer Biology Satellite Meeting, New Zealand, 28-29 August 2016.

Oral and poster: Thomas P, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK. The ghrelin receptor antisense long non-coding RNA, GHSROS, regulates prostate cancer growth and survival and can be targeted with a locked antisense oligonucleotide. The Endocrine Society of Australia (ESA) Annual Meeting, Gold Coast, 21-24 August 2016.

One invited presentation, one oral and two posters at the Princess Alexandra Hospital Health Symposium, 1–3 August 2016:

Invited speaker: Dr Handoo Rhee. Pilot study to evaluate the prognostic and metabolic benefits of metformin during androgen deprivation therapy in metastatic prostate cancer.

Oral: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Joshi A, Nicholson C, Rhee H, Thomas P, Miles K, Gustafson S, Parterdis J, Malone G, Pryor D, Lehman M, Lawson M, Munns J, Chung E, Preston J, Vela I, Heathcote P, Wood S. Hybrid PET/MRI system for targeting PSMA expression in local and metastatic prostate foci.

Poster: Subramaniam S, Jeet V, Walpole C, Nelson C, Clements J, Batra J. Determining the functional roles of PDK1and MCAT genes in prostate cancer.  

Oral: Matin F, Moya L, Jeet V, Clements J, Batra J. Breaking the Wall of Prostate Cancer Detection, Falling Walls Lab, Canberra, August 2016

The Australia New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Brisbane, 10 – 12 July 2016:

Poster: Rhee H, Gunter J, Nicholson C, Jovanovic L, Williams E, Hollier B, Nelson C. Update on androgen deprivation therapy and adjuvant metformin (ADMET) trial for men with treatment naïve metastatic prostate cancer.

Poster: Rhee H, Gunter J, Nicholson C, Jovanovic L, Williams E, Hollier B, Nelson C, Vela I, Persistence of Circulating Tumour Cells in men treated with Androgen Deprivation Therapy can be used to enrich and propagate temporary personalised cell lines.

Poster: Rhee H, Thomas P, Shepherd B, Greenslade S, Vela I, Russell PJ, Nelson CC, Chung E, Wood G, Malone G, Wood S, Heathcote P. PSMA PET improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: implications for selection and assessment for active surveillance and focal therapy.

Poster: Joshi A, Nicholson C, Hutchinson A, Tevz G, Hollier B, McPherson S, Rhee H, Williams E, Vela I, Prostate cancer xenograft in vitro culture using organoid technology.

Poster: Kanagarajah A, Rhee H, Vela I, Lawson M, Munns J, McCaffrey E, Lehman M, Pryor D, Malone G, Preston J, Chung E, Heathcote P, Wood S, Multidisciplinary Team approach to interpreting PSMA PET data in men with prostate cancer. 

Poster: Patel A, Rhee H, Heathcote P, Lawson M, Preston J, Vela I, Pryor D, Lehman M, Wood S.  Outcomes of salvage lymph node dissection for oligometastatic recurrent prostate cancer after radical prostatectomy: Results of a single-institution Multidisciplinary Team series.

MASCC/ISOO 2016 Annual Meeting, Adelaide, 23-25 June 2016.

Poster: Beatty L, Kemp E, Butow P, Turner J, Milne D, Yates P, Yip D, Lambert S, Koczwara B. Finding my way: uptake and predictors of adherence to an online psychological intervention for cancer-related distress.

TRI Friday Seminar Series, 17 June 2016.

Oral: Matin F. The Therapeutic Potential of MicroRNAs in Prostate Cancer.

The Australian Society for Medical Research (ASMR) Postgraduate Student Conference, Brisbane, 2 June 2016:

Oral: Thomas PB. The long non-coding RNA, GHSROS, mediated prostate cancer growth. (awarded second prize for best oral presentation).

Poster: Panchadsaram J, Tevz G, Nelson C, The Australian Prostate Cancer BioResource, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen-mediated expression of IRX4.

Poster: Matin F, Moya L, Jeet V, Clements J, Batra J. MicroRNAs in plasma: Potential minimally invasive markers for aggressive prostate cancer screening.

Poster: Subramaniam S, Walpole C, Clements J, Batra J. Functional roles of the MCAT and PDK1 genes in prostate cancer.

Poster: Srinivasan S, Stephens C, Clements J, Batra J. Exploring the function of prostate cancer-associated germline variants in the PSA gene.

18th European Congress of Endocrinology, Munich, Germany, 28 May 2016 - 31 May 2016

Poster: Panchadsaram J, Tevz G, Stylianou N, Hollier B, Nelson C, Williams E, Clements J, Batra J. A prostate cancer risk associated polymorphism regulates androgen mediated regulation of a novel long noncoding RNA, IRX4lncRNA. 

TRI Friday Seminar Series. 27 May 2016.

Oral: Volpert M. Targeting Neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.

10th World Biomaterials Congress, Montreal, Canada, 17 – 22 May 2016 (merit award)

Oral: Shokoohmand A, Bock N, Clements JA, Hutmacher DW. An advanced bioengineered 3D model mimicking prostate cancer-induced bone metastasis microenvironment.

TRI Cancer Seminar. 20 May 2016.

Oral: Subramaniam S. Functional role of the MCAT and PDK1 genes in prostate cancer and their regulation by miRNAs.

 Cancer Nurses Society of Australia 19th Annual Congress, Cairns, 12 - 14 May 2016.

Poster: Leutenegger J, Gavin N, Yates P. The tyranny of distance – can tele-oncology bridge the gap between rural and remote and tertiary facilities.

The 111th American Urological Association Annual Meeting, San Diego, USA, 6-10 May 2016:

Poster: Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Nelson C, Vela I. Persistence of Circulating Tumour Cells (CTCs) in men treated with Androgen Deprivation Therapy can be used to enrich and propagate temporary personalized cell lines.

Poster: Nicholson C, Williams E, Hutchinson A, Vela I, In vitro culture of prostate cancer xenografts using organoid technology.

International Society for Extracellular Vesicles (ISEV) 2016 Conference, Rotterdam, The Netherlands, 4 – 7 May 2016

Poster: Soekmadji C, Lehman M, An J, Riches JD, Nelson CC. Identifying extracellular vesicles-derived miRNAs in advanced prostate cancer. .

Oncology Nursing Society 41st Annual Congress, San Antonio, USA, 28 April - 1 May 2016.

Poster: Yates P, Impact of specialist prostate cancer nurses on patient reported and health service outcomes: A comparative effectiveness study. 

The Urological Society of Australia and New Zealand 69th Annual Scientific Meeting, Gold Coast, 16 – 19 April 2016:

Invited speaker: Vela I. Test tube urology – update on the current molecular frontiers in Urology.

Oral: Hutchinson A, Nicholson C, Williams E, Vela I. In vitro culture of prostate cancer xenografts using organoid technology.

Poster: Nicholson C, Rhee H, Thomas P, Miles K, Greenslade S, Pryor D, Lehman M, Heathcote P, Vela I, Wood S. Histopathological correlation of lesions identified by hybrid PET/MRI using novel 68 Ga PSMA inhibitor.

Poster: Kanagarajah A, Rhee H, Vela I, Lawson M, Wood G, Paterdis J, Malone G, Preston J, Heathcote P, Wood S. Multi-Disciplinary team initiated 68 Ga PSMA PET/CT can be used to change patient treatment outcomes.

The Endocrine Society's 98th Annual Meeting (ENDO 2016), Boston, USA, 1 - 4 April 2016:

Invited Chair: Nelson C. ENDO Scientific Symposium entitled: Fueling Hormone-Dependent Cancers: Lifestyle to Lipids.

Poster: Thomas PB, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK. Targeting the Long Non-Coding RNA GHSROS, a Mediator of Prostate Cancer Tumour Growth, with Short Antisense Oligonucleotides. (Awarded presidential poster prize).

TRI Cancer Seminar, Brisbane, 16 March 2016.

Oral: Srinivasan S. Prostate Cancer risk associated PSA germline variants regulate its protease function.

The European Association of Urology Conference, Munich, Germany, 11 – 16 March 2016:

Poster: Rhee H, Gunter JH, Jovanovic L, Williams ED, Hollier BG, Nelson CC, Vela I, Delivery of precision medicine in advanced prostate cancer using circulating tumour cells (CTCs).

Poster: Rhee H, Thomas P, Shepherd B, Greenslade S, Vela I, Russell PJ, Nelson CC, Chung E, Wood G, Malone G, Wood S, Heathcote P. PSMA PET improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: implications for selection and assessment for active surveillance and focal therapy.

Poster: Nicholson C, Joshi A, Hutchinson A, Tevz G, Hollier BG, McPherson S, Rhee H, Williams ED, Vela I, Prostate cancer xenograft in vitro culture using organoid technology.

The TRI Cancer Seminar, Brisbane, 4 March 2016:

Oral: Maharaj M. Post-translational modifications that regulate the receptor tyrosine kinase, EphB4.

Oral: Tevz G. Unveiling the transcriptional complexity at RLN1/RLN2 genomic locus in prostate cancer using PacBio Iso-seq and strand specific RNA-Seq.
 

TRI Friday Seminar Series, 5 February 2016.

Oral: Mosaad EMO, 3D Prostate cancer drug testing platform.

IGF-Oz 2016, Victoria, 4-5 February 2016.

Session chair and invited speaker: Nelson C. The role of insulin in prostate cancer progression.